26.50
-1.30 (-4.68%)
| Previous Close | 27.80 |
| Volume | 259,004 |
| Price / Sales | 9.57 |
| Price / Book | 9.08 |
| 52 Weeks Range |
| Profit Margin | -62.50% |
| Operating Margin (TTM) | -69.33% |
| Diluted EPS (TTM) | -1.25 |
| Quarterly Revenue Growth (YOY) | 42.30% |
| Total Debt/Equity (MRQ) | 12.03% |
| Current Ratio (MRQ) | 17.36 |
| Operating Cash Flow (TTM) | -36.90 M |
| Levered Free Cash Flow (TTM) | -26.02 M |
| Return on Assets (TTM) | -17.46% |
| Return on Equity (TTM) | -41.39% |
News Mood
AIStockmoo Score
| Value 30% | 0.0 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | 3.4 |
| From our AI technical analysis of the chart. info | NA |
| Uptrend over the past year. Trading near its 52-week high. info | |
| Price and its moving averages are lined up in an uptrend. Its main moving average is rising. Close to its rising moving average. A recent move above resistance has not been confirmed. info | |
| Candle Patterns info | NA |
| Above its medium-term trend line. info | |
| Sentiment 20% | 0.8 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Smart Money 20% | 0.0 |
| No clear net insider buying or selling. info | |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is high against its 52-week average. info | |
| Short-term momentum fading. info | |
| Price is between support and resistance. info | |
| Final Score | 1.28 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | CeriBell, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CBLL | - | - | - | 9.08 |
| UFPT | - | - | - | 4.88 |
| NNOX | - | - | - | 0.310 |
| QTI | - | - | - | 13.92 |
| AXGN | - | - | - | 6.12 |
| ESTA | - | - | - | 128.59 |
Select this tab to load the latest available analysis.
|
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 10.54% |
| % Held by Institutions | 84.45% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Nov 2026 | Yahoo Finance |
CeriBell (CBLL) Climbed, What Is Behind The Fresh Attention?
CeriBell guidance hike and delirium launch draw investor focus CeriBell (CBLL) has lifted its 2026 revenue outlook to US$115 million to US$117 million, while rolling out an FDA-cleared delirium monitoring solution that now qualifies for additional CMS reimbursement. CeriBell’s guidance hike and… |
| 06 Nov 2026 | Yahoo Finance |
Ceribell (CBLL) Stock Gets Fair Value Bump As Analysts Back Rapid EEG Growth
Ceribell’s updated analyst narrative now centers on a fair value estimate that increased from about US$27.00 to about US$29.57 per share. This change aligns with recent Street commentary that focuses on current execution in rapid EEG, new clinical indications, and how these trends shape… |
| 04 Nov 2026 | Yahoo Finance |
How Raised Revenue Guidance At CeriBell (CBLL) Has Changed Its Investment Story
CeriBell reported third quarter 2026 revenue of US$29.34 million and a net loss of US$21.35 million, and raised full year revenue guidance to a range of US$115 million to US$117 million following the commercial launch of its FDA cleared delirium monitoring solution. The new delirium monitoring… |
| 04 Nov 2026 | Yahoo Finance |
CeriBell Inc (CBLL) (Q3 2026) Earnings Call Highlights: Record Hospital Additions and 30% ...
CeriBell Inc (CBLL) posted 30% revenue growth to $29.3 million with a record 35 new hospitals and 90% gross margin, though net loss widened to $21.4 million amid heavy growth investment. |
| 04 Nov 2026 | Yahoo Finance |
CeriBell, Inc. Q3 2026 Earnings Call Summary
Moby summary of CeriBell, Inc.'s Q3 2026 earnings call… |
| 04 Nov 2026 | Yahoo Finance |
CeriBell (CBLL) Q3 2026 Earnings Call Transcript
Management details why market penetration under 4% signals runway. |
| 03 Nov 2026 | Yahoo Finance |
CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates
CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of +4.00% and +0.70%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 03 Nov 2026 | Yahoo Finance |
Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics
The headline numbers for CeriBell, Inc. (CBLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
| 03 Nov 2026 | Yahoo Finance |
CeriBell Q3 Earnings Call Highlights
CeriBell (NASDAQ:CBLL) reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among existing customers. Management also outlined plans to commercially launch its Delirium Monitoring S… |
| 03 Nov 2026 | Yahoo Finance |
Ceribell Reports Third Quarter 2026 Financial Results
SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the third quarter ended September… |
| 02 Nov 2026 | Yahoo Finance |
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
Commercial launch follows successful pilot, with customers reporting improved clinical decision-making and greater confidence in care decisionsSUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on… |
| 30 Oct 2026 | Yahoo Finance |
Is CeriBell (CBLL) Fully Priced After A 133% One Year Run?
CeriBell has delivered a sharp move over the past year, which naturally puts its current share price under the microscope. The question for you is whether the recent trading level lines up with what the business is generating through its sales. Over the past 12 months, CeriBell has returned 133.2%… |
| 28 Oct 2026 | Yahoo Finance |
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a… |
| 25 Oct 2026 | Yahoo Finance |
3 AI Stocks To Own In October 2026
AI risk is suddenly front-page news. Financiers are warning that high valuations and concentrated exposure in artificial intelligence could feed the next market downturn, yet the same technology is quietly reshaping how smaller specialists build tools in automation, data and machine learning. That… |
| 24 Oct 2026 | Yahoo Finance |
Pfizer And 2 Other AI Healthcare Stocks To Watch
Warning signs around heavily indebted AI infrastructure firms have grown louder after analysts raised the risk of a tech debt spiral, with some newer players struggling to finance data centers and high-end chips. That strain shifts attention toward more grounded uses of AI that address urgent… |
| 20 Oct 2026 | Yahoo Finance |
Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third… |
| 18 Oct 2026 | Yahoo Finance |
CeriBell And These 2 AI Stocks To Watch
America’s planned AI build-out faces funding strains and project delays, yet the race to add computing power has not stopped. When big data centre projects hit financing walls, attention often shifts to smaller, more focused AI players that do not need multi billion dollar budgets to move the… |
| 17 Oct 2026 | Yahoo Finance |
3 AI Healthcare Stocks To Own In October 2026
Anthropic recently suggested AI could lift the US economy by nearly 50% by 2030, which shows how much value smarter software might create. Healthcare is one of the clearest places where that shift becomes real for patients and for capital. This article unpacks three AI driven healthcare stocks from… |
| 14 Oct 2026 | Yahoo Finance |
Is CeriBell’s (CBLL) Expanded EEG Software Deepening Its Moat in Critical Care Monitoring?
CeriBell, Inc. previously announced that the FDA cleared new software for its Ceribell System, adding bedside brain-activity trend tools like Alpha-Delta Ratio and amplitude-integrated EEG to help clinicians interpret complex EEG data more quickly across neonatal and adult critical care settings.… |
| 13 Oct 2026 | Yahoo Finance |
CeriBell (CBLL) After FDA Clearance Looks Pricey Despite Stronger Adoption Hopes
CeriBell (CBLL) drew investor attention after the FDA cleared new software for its Ceribell System, expanding bedside EEG tools that help clinicians read complex brain activity data more quickly in critical care. CeriBell has seen momentum build over 2026, with the share price at $26.14 and a 90… |
| Show more | ||
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |